- Ligand Partner Verona Pharma Announces FDA Approval of Ohtuvayre™ (ensifentrine), First Inhaled Novel Mechanism for Maintenance Treatment of COPD in More Than 20 Years
- Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Adults
- Ligand to Participate in Upcoming Investor Conferences
- Ligand Reports First Quarter 2024 Financial Results
- Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement
- Ligand to Report First Quarter 2024 Financial Results on May 7, 2024
- Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference
More ▼
Key statistics
As of last trade Ligand Pharmaceuticals Inc (LGND:NMQ) traded at 82.79, -12.46% below its 52-week high of 94.57, set on Feb 27, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 84.90 |
---|---|
High | 84.90 |
Low | 82.35 |
Bid | 82.71 |
Offer | 82.92 |
Previous close | 84.79 |
Average volume | 133.01k |
---|---|
Shares outstanding | 17.96m |
Free float | 17.54m |
P/E (TTM) | 16.20 |
Market cap | 1.52bn USD |
EPS (TTM) | 5.23 USD |
Data delayed at least 15 minutes, as of Jul 03 2024 16:06 BST.
More ▼